MUC-1 Vaccine Delays Breast Cancer Distant Recurrence & Extends Survival

Oncology Times - OncTimes Talk

English - June 25, 2024 22:17 - 9 minutes - 81 KB - ★★★★ - 2 ratings
Science Health & Fitness Medicine oncology cancer medicine health news Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Telehealth Triumphs for Palliative Care Delivery in Patients With Lung Cancer

Next Episode: A Multi-Drug Algorithm Used to Accurately Predict Best First-Line Treatments in Patients With Newly Diagnosed Acute Myeloid Leukemia

When the mucin-1 (MUC-1) vaccine tecemotide was added to standard-of-care neoadjuvant systemic therapy, investigators in Austria found improved long-term outcomes in women with early breast cancer. Individuals vaccinated with tecemotide had markedly longer distant recurrence-free and overall survival. This was in the randomized prospective ABCSG-34 trial presented at the 2024 ASCO Annual Meeting.

Oncology Times reporter Peter Goodwin met up in Chicago with the lead study author, Christian F. Singer MD, a gynecologist specializing in breast cancer at the Department of Obstetrics and Gynecology and the Comprehensive Cancer Center of the Medical University of Vienna, in Vienna, Austria.